Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...

Through the deal, Celgene gains Gloucester's romidepsin (Istodax), a histone deacetylase (HDAC) inhibitor, which was approved by the FDA in November 2009 to treat cutaneous T cell lymphoma (CTCL ...

Bristol-Myers Squibb's HDAC inhibitor Istodax has been on the US market for a decade as a treatment for peripheral T-cell lymphoma (PTCL), but will now be withdrawn from sale after a failed phase ...

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH), a micro-cap pharmaceutical company with a market capitalization of $3.12 million, has amended its agreement with contract research organization ...

Short-chain fatty acids (SCFAs) like propionate and butyrate are critical byproducts of dietary fiber digestion. These ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Suzhou Puhe Biopharma Co. Ltd. has disclosed histone deacetylase 1 (HDAC1) inhibitors acting as REST Corepressor 1 (RCOR1; CoREST)/histone deacetylase (HDAC) complex inhibitors reported to be useful ...

In early November, Viracta said it would be waving goodbye to 42% of its remaining staff in order to keep money flowing to its lead program, a combination of the HDAC inhibitor nanatinostat and ...

The claims also include combination therapies comprising use of the hedgehog pathway inhibitors along with an HDAC inhibitors enhancing anti-cancer efficacy. “Issuance of the new patent for our ...

Suzhou Puhe Biopharma Co. Ltd. has disclosed histone deacetylase 1 (HDAC1) inhibitors acting as REST Corepressor 1 (RCOR1; CoREST)/histone deacetylase (HDAC) complex inhibitors reported to be useful ...